"‘Immunotransplant’ Shows Potential For Non-Hodgkin Lymphoma" - Jennifer Southall
A combination of immunotherapy and stem cell transplantation could benefit patients with treatment-resistant non-Hodgkin lymphoma, according to preclinical data published in Cancer Discovery. “Using immunotransplant to enhance the efficacy of checkpoint blockade therapy could be broadly significant as these immunotherapies are a standard therapy for melanoma, kidney cancer, lung cancer and others,” said study author Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. He added, “Even for settings in which checkpoint blockade therapy proves ineffective, our data suggest that its efficacy may be ‘rescued’ by immunotransplant. This research also suggests that the addition of checkpoint blockade may improve other T-cell therapies, such as chimeric antigen receptor T-cell therapy.”
—Joshua Brody, MD, Director, Lymphoma Immunotherapy Program, The Tisch Cancer Institute, Assistant Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai
Mount Sinai Researchers Make Immunotherapy Work for Treatment-Resistant Lymphoma
Aug 02, 2019 View All Press ReleasesMount Sinai Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
Apr 08, 2019 View All Press Releases